People receiving Johnson & Johnson’s COVID-19 vaccine may benefit more than Moderna or the Pfizer booster shot, preliminary data from a US study revealed on Wednesday, a finding that comes on the same day that the Food and Drug Administration raised some concerns. Test data from J&J’s booster shots.
funded by the National Institutes of Health Study 458 adults were screened on a mix and match of COVID-19 vaccines, who received one of three US approved vaccines—Pfizer, Moderna or J&J—and subsequently received booster shots.
The researchers analyzed antibody levels among the participants 15 days after the booster shot.
In people who originally received the J&J shot, antibody levels were four times higher after a J&J booster, 35 times higher after a Pfizer booster, and 76 times higher after a Moderna booster.
The study also found that Moderna recipients had higher antibody levels “despite being administered the booster vaccine,” when compared to those who were initially vaccinated with either Pfizer or J&J vaccines.
The study found no safety concerns with mixing and matching vaccines.
14.9 million. This is the total number of people in the US who have received the single-dose J&J Covid-19 vaccine, According to Centers for Disease Control and Prevention (CDC). The CDC’s tracker also shows that 10,029 people have received a J&J booster dose, although it has not been formally approved by the FDA.
what to see
The findings of the NIH-funded study and a mixed review of J&J’s booster shots data by the FDA may lead to debate about which booster shots will be offered to the nearly 15 million recipients of the single-dose vaccine. So far, the supply of mRNA vaccines from Pfizer and Moderna far exceeds the shot in Jammu and Kashmir. According to CDC data, Pfizer had distributed more than 273 million doses and Moderna had distributed more than 191 million doses, compared to J&K’s 23.5 million.
Earlier on Wednesday, the Food and Drug Administration published its analysis of J&J’s vaccine booster and noted that it appeared to be beneficial but the company questioned the sensitivity of the test used in its trials. Data shared by the vaccine manufacturer showed that a second dose of the J&J shot, given two months after the first dose, increased its effectiveness in preventing the disease by 75%. However, J&J’s data was not submitted in time for regulators to independently verify the company’s analysis, the FDA said in its document. The authors of the FDA document expressed concern that the test used by the company to measure the immune response in some trial participants may not be sensitive enough and therefore may overestimate efficacy. The FDA advisory panel will meet on Friday to consider recommending the use of the J&J booster shot. Last month, the agency authorized a Pfizer booster dose for seniors and other high-risk patients.
FDA Says J&J Covid Booster Possibly Boosts Immunity, But Evidence Isn’t Silly (Businesshala)